Immunovant, Inc. IMVT
As ofNov 20, 2026, 10:54 AM EST
- YTD
- +26.91%
- 1 year
- +41.55%
- Market cap
- 6.67B
- EPS (ttm)
- -2.56
- Shares out
- 206.95M
- Forward P/E
- -11.53
- YTD return
- +26.91%
- 1-year return
- +41.55%
- 50-day average
- 32.28
- 200-day average
- 32.46
- Enterprise value
- 6.14B
- Price / book
- 10.24
- Volume
- 105.67K
- Avg volume
- 1.42M
- Open
- 32.07
- Previous close
- 32.52
- Day's range
- 32.02 – 32.77
- 52-week range
- 21.86 – 45.42
- Beta
- 0.94
- Analysts
- Buy
- Price target
- 48.63 (+50.7%)
- Earnings date
- Feb 5, 2027
Key statistics
- Free cash flow
- -230.54M
- Total cash
- 722.27M
- Return on equity
- -86.51%
- Short % of float
- 19.91%
Fundamental scorecard
6 of 25 checks passed on IMVT’s reported financials
6of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 33.00
- Target (mean)
- 48.63
- Target (high)
- 62.00
- Strong buy2
- Buy11
- Hold4
- Sell0
- Strong sell0
Next earnings
Feb 5, 2027
Expected Feb 5, 2027. Consensus EPS estimate -0.72212.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 5, 2027 | Dec 30, 2026 | -0.64 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | -0.73701 | -0.47 | +0.27 | +36.23% |
| Aug 6, 2026 | Jun 30, 2026 | -0.6289 | -0.75 | -0.12 | -19.26% |
| May 20, 2026 | Mar 31, 2026 | -0.59202 | -0.73 | -0.14 | -23.31% |
| Feb 6, 2026 | Dec 31, 2025 | -0.72 | -0.61 | +0.11 | +15.28% |
| Nov 10, 2025 | Sep 30, 2025 | -0.72 | -0.73 | -0.01 | -1.39% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | Truist Securities | main | Hold | Hold |
| Nov 10, 2026 | Wells Fargo | main | Overweight | Overweight |
| Aug 4, 2026 | JP Morgan | main | Overweight | Overweight |
| Jun 30, 2026 | Citigroup | main | Buy | Buy |
| May 26, 2026 | Guggenheim | main | Buy | Buy |
| May 22, 2026 | Truist Securities | main | Hold | Hold |
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- immunovant.com
News
David Einhorn Bets on Aluminum in Q3: Here Are His New Stock Picks, Fund Changes Truist Securities Maintains Hold on Immunovant, Raises Price Target to $33
Wells Fargo Maintains Overweight on Immunovant, Raises Price Target to $47
Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Study
KKR, Constellation Energy On Deck Monday As Private Credit, Power Face Test
Your note
Sign in to keep a note on IMVT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARNETT EVA RENEE | Chief Financial Officer | Sale | Apr 15, 2025 | 396,774 |
| GEFFNER MICHAEL | Officer | Sale | Oct 21, 2025 | 217,958 |
| GIRÃO TIAGO M | Chief Financial Officer | Sale | Jul 22, 2026 | 240,798 |
| GLORIA MELANIE | Chief Operating Officer | Sale | Aug 19, 2026 | 219,301 |
| LEVINE MARK S | Officer | Sale | Nov 19, 2024 | 319,228 |
| MACIAS WILLIAM L | Officer | Sale | Feb 18, 2025 | 357,353 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 7.59% | 15,704,154 | 510.70M | Sep 29, 2026 |
| Deep Track Capital, Lp | 4.43% | 9,160,801 | 297.91M | Sep 29, 2026 |
| Blackrock Inc. | 3.59% | 7,425,771 | 241.49M | Sep 29, 2026 |
| Farallon Capital Management LLC | 3.13% | 6,471,000 | 210.44M | Sep 29, 2026 |
| Morgan Stanley | 2.75% | 5,684,840 | 184.87M | Sep 29, 2026 |
| Two Seas Capital Lp | 2.23% | 4,612,692 | 150.00M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.46% | 5,092,337 | 165.60M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.26% | 2,600,086 | 84.55M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.09% | 2,251,148 | 73.21M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.02% | 2,107,163 | 68.52M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 0.91% | 1,881,798 | 61.20M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.68% | 1,408,872 | 45.82M | Sep 29, 2026 |
